BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy.

V. Panou (Odense & Aalborg, Denmark), A. Louw (Perth, Australia), W. Szejniuk (Aalborg, Denmark), C. Meristoudis (Aalborg, Denmark), S. Chai (Perth, Australia), L. Lynggård Andersen (Aalborg, Denmark), A. Birbaneh Asghari (Aalborg, Denmark), M. Vyberg (Aalborg, Denmark), J. Hansen (Copenhagen, Denmark), J. Creaney (Perth, Australia), O. Røe (Levanger & Trondheim, Norway)

Source: Virtual Congress 2020 – Malignant pleural effusion in 2020: understanding the biology and clinical implications
Disease area: Thoracic oncology

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Panou (Odense & Aalborg, Denmark), A. Louw (Perth, Australia), W. Szejniuk (Aalborg, Denmark), C. Meristoudis (Aalborg, Denmark), S. Chai (Perth, Australia), L. Lynggård Andersen (Aalborg, Denmark), A. Birbaneh Asghari (Aalborg, Denmark), M. Vyberg (Aalborg, Denmark), J. Hansen (Copenhagen, Denmark), J. Creaney (Perth, Australia), O. Røe (Levanger & Trondheim, Norway). BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy.. 4490

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: